<p>辉瑞公司（NYSE:PFE - 获取免费报告）的股票目前被 17 家评级公司评定为 “适度买入”，MarketBeat 报道。一位分析师给予该股票卖出评级，八位分析师给予持有评级，五位分析师给予买入评级，三位分析师给予强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 31.07 美元。</p>
<ul>
<li>作为摩根大通提升吉利德评级的两只医疗股</li>
</ul>
<p>几位分析师对该股票发布了报告。花旗集团在 3 月 27 日的研究报告中重申了对辉瑞股票的 “中性” 评级。汇丰全球研究在 3 月 10 日的研究报告中将辉瑞股票的评级提升至 “强烈买入”。Truist Financial 在 12 月 18 日的报告中将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并给予该公司 “买入” 评级。古根海姆在 3 月 18 日的研究报告中重申了对辉瑞股票的 “买入” 评级。最后，高盛集团在 4 月 8 日的报告中重新发布了 “中性” 评级，并将辉瑞股票的目标价设定为 25.00 美元（低于 32.00 美元）。</p>
<p><strong>阅读我们对 PFE 的最新分析</strong></p>
<h2>辉瑞股票上涨 1.4%</h2>
<ul>
<li>维京治疗公司：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）周五开盘价为 21.89 美元。该公司的市值为 1241.4 亿美元，市盈率为 15.52，市盈增长比率为 0.64，贝塔值为 0.67。公司的 50 日移动平均价格为 25.25 美元，200 日移动平均价格为 26.40 美元。公司的债务股本比率为 0.63，流动比率为 1.00，速动比率为 0.73。辉瑞的年低为 20.92 美元，年高为 31.54 美元。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近一次发布季度财报是在 2 月 4 日。该生物制药公司报告本季度每股收益为 0.63 美元，超出分析师一致预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司本季度的收入为 177.6 亿美元，而分析师一致预期为 172.6 亿美元。去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 24.7%。分析师平均预测辉瑞在当前财政年度的每股收益为 2.95 美元。</p>
<h2>内部人士买卖情况</h2>
<ul>
<li>这些股票的收益未达预期，但下季度将反弹</li>
</ul>
<p>在相关消息中，董事罗纳德·E·布莱洛克于 2 月 13 日购买了 19,457 股公司的股票。该股票的平均购买价格为每股 25.65 美元，总价值为 499,072.05 美元。收购完成后，该董事现在拥有 27,707 股公司的股票，价值 710,684.55 美元。这笔交易使他们的持股增加了 235.84%。该购买在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。目前，0.06% 的股票由公司内部人士持有。</p>
<h2>对辉瑞的对冲基金看法</h2>
<p>几位大型投资者最近买入和卖出了该公司的股票。退休财富解决方案公司在第四季度新购入辉瑞股票，价值约 26,000 美元。Rialto Wealth Management LLC 在第四季度新购入辉瑞股票，价值 26,000 美元。Clarity Asset Management Inc.在第四季度新购入辉瑞股票，价值 27,000 美元。Gould Capital LLC 在第四季度将其在辉瑞的持股增加了 97.2%。Gould Capital LLC 现在拥有 1,000 股该生物制药公司的股票，价值 27,000 美元，此前在上个季度又购买了 493 股。最后，Kohmann Bosshard Financial Services LLC 在第四季度新购入辉瑞股票，价值 28,000 美元。目前 68.36% 的股票由机构投资者持有。</p>
<h2>辉瑞公司简介</h2>
<p>（获取免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际市场上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来可能的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比辉瑞更好</li>
<li>成长投资：你应该在 2022 年采用这种投资策略吗？</li>
<li>Robinhood 策略可能会改变年轻投资者的游戏规则</li>
<li>股票中的死亡交叉是什么？</li>
<li>这三只零售股票是被低估还是确实有问题？</li>
<li>投资旅游股票的好处</li>
<li>IONQ 和 RGTI 加入 DARPA 量子计划：高风险在前</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
<p>在你考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>辉瑞公司（NYSE:PFE）获得了 17 家券商的 “适度买入” 共识评级。评级包括一项卖出，八项持有，五项买入和三项强烈买入。12 个月的平均目标价格为 31.07 美元。最近的报告显示，花旗集团维持 “中性” 评级，而汇丰银行则上调至 “强烈买入”。辉瑞的股票开盘价为 21.89 美元，市值为 1241.4 亿美元。该公司报告每股收益为 0.63 美元，超出预期，收入为 177.6 亿美元，同比增长 24.7%。内部人士购股情况被注意到，68.36% 的股份由机构投资者持有</p>

<p>Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) have been assigned a consensus rating of &#34;Moderate Buy&#34; from the seventeen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating, five have issued a buy rating and three have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $31.07.</p>
<div class="lb-trans"><p>辉瑞公司（NYSE:PFE - 获取免费报告）的股票目前被 17 家评级公司评定为 “适度买入”，MarketBeat 报道。一位分析师给予该股票卖出评级，八位分析师给予持有评级，五位分析师给予买入评级，三位分析师给予强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价为 31.07 美元。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>作为摩根大通提升吉利德评级的两只医疗股</li>
</ul>
</div><p>Several analysts have issued reports on the stock. Citigroup reaffirmed a &#34;neutral&#34; rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a &#34;strong-buy&#34; rating in a research note on Monday, March 10th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, December 18th. Guggenheim reaffirmed a &#34;buy&#34; rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a &#34;neutral&#34; rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th.</p>
<div class="lb-trans"><p>几位分析师对该股票发布了报告。花旗集团在 3 月 27 日的研究报告中重申了对辉瑞股票的 “中性” 评级。汇丰全球研究在 3 月 10 日的研究报告中将辉瑞股票的评级提升至 “强烈买入”。Truist Financial 在 12 月 18 日的报告中将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并给予该公司 “买入” 评级。古根海姆在 3 月 18 日的研究报告中重申了对辉瑞股票的 “买入” 评级。最后，高盛集团在 4 月 8 日的报告中重新发布了 “中性” 评级，并将辉瑞股票的目标价设定为 25.00 美元（低于 32.00 美元）。</p>
</div><p><strong>Read Our Latest Analysis on PFE</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 PFE 的最新分析</strong></p>
</div><h2>Pfizer Trading Up 1.4 %</h2>
<div class="lb-trans"><h2>辉瑞股票上涨 1.4%</h2>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>维京治疗公司：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p>Shares of NYSE:PFE opened at $21.89 on Friday. The stock has a market capitalization of $124.14 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company's 50-day moving average price is $25.25 and its two-hundred day moving average price is $26.40. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer has a one year low of $20.92 and a one year high of $31.54.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）周五开盘价为 21.89 美元。该公司的市值为 1241.4 亿美元，市盈率为 15.52，市盈增长比率为 0.64，贝塔值为 0.67。公司的 50 日移动平均价格为 25.25 美元，200 日移动平均价格为 26.40 美元。公司的债务股本比率为 0.63，流动比率为 1.00，速动比率为 0.73。辉瑞的年低为 20.92 美元，年高为 31.54 美元。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 earnings per share. The business's revenue was up 24.7% compared to the same quarter last year. On average, equities analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近一次发布季度财报是在 2 月 4 日。该生物制药公司报告本季度每股收益为 0.63 美元，超出分析师一致预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司本季度的收入为 177.6 亿美元，而分析师一致预期为 172.6 亿美元。去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 24.7%。分析师平均预测辉瑞在当前财政年度的每股收益为 2.95 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><ul>
<li>These Stocks Missed on Earnings, But Will Rebound Next Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>这些股票的收益未达预期，但下季度将反弹</li>
</ul>
</div><p>In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事罗纳德·E·布莱洛克于 2 月 13 日购买了 19,457 股公司的股票。该股票的平均购买价格为每股 25.65 美元，总价值为 499,072.05 美元。收购完成后，该董事现在拥有 27,707 股公司的股票，价值 710,684.55 美元。这笔交易使他们的持股增加了 235.84%。该购买在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。目前，0.06% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Pfizer</h2>
<div class="lb-trans"><h2>对辉瑞的对冲基金看法</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC raised its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at $28,000. 68.36% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几位大型投资者最近买入和卖出了该公司的股票。退休财富解决方案公司在第四季度新购入辉瑞股票，价值约 26,000 美元。Rialto Wealth Management LLC 在第四季度新购入辉瑞股票，价值 26,000 美元。Clarity Asset Management Inc.在第四季度新购入辉瑞股票，价值 27,000 美元。Gould Capital LLC 在第四季度将其在辉瑞的持股增加了 97.2%。Gould Capital LLC 现在拥有 1,000 股该生物制药公司的股票，价值 27,000 美元，此前在上个季度又购买了 493 股。最后，Kohmann Bosshard Financial Services LLC 在第四季度新购入辉瑞股票，价值 28,000 美元。目前 68.36% 的股票由机构投资者持有。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际市场上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来可能的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>Robinhood Strategies Could Be a Game-Changer for Young Investors</li>
<li>What is a Death Cross in Stocks?</li>
<li>Are These 3 Retail Stocks Oversold or Really in Trouble?</li>
<li>Investing in Travel Stocks Benefits</li>
<li>IONQ &amp; RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比辉瑞更好</li>
<li>成长投资：你应该在 2022 年采用这种投资策略吗？</li>
<li>Robinhood 策略可能会改变年轻投资者的游戏规则</li>
<li>股票中的死亡交叉是什么？</li>
<li>这三只零售股票是被低估还是确实有问题？</li>
<li>投资旅游股票的好处</li>
<li>IONQ 和 RGTI 加入 DARPA 量子计划：高风险在前</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

- Pfizer Inc. 获得 “适度买入” 评级，分析师目标价为 $31.07。  
- 公司最新季度收益为 $0.63，超出预期，收入同比增长 24.7%。  
- 68.36% 的股份由机构投资者持有，内部人士持股比例为 0.06%。  

辉瑞公司（纽约证券交易所代码：PFE）被券商一致推荐为 “适度买入”